vs
AtriCure, Inc.（ATRC）与Rocket Lab Corp（RKLB）财务数据对比。点击上方公司名可切换其他公司
Rocket Lab Corp的季度营收约是AtriCure, Inc.的1.3倍（$179.7M vs $140.5M），Rocket Lab Corp同比增速更快（35.7% vs 13.1%），AtriCure, Inc.自由现金流更多（$18.4M vs $-114.2M），过去两年Rocket Lab Corp的营收复合增速更高（39.2% vs 13.6%）
AtriCure是一家专注于心房颤动及相关心脏病症治疗的医疗设备企业，研发并生产创新外科手术工具与疗法，主要服务北美、欧洲、亚太地区的医院、心脏外科中心及医疗机构，为微创心脏手术提供高效可靠的适配解决方案。
Rocket Lab是公开上市的航空航天制造商及发射服务提供商，旗下Electron轨道火箭主打小型卫星发射，截至2026年1月已成功完成超75次任务，是全球现役发射次数最多的小型运载火箭。公司还开发了Electron的亚轨道改型HASTE用作高超音速技术测试平台，下一代可复用中型运载火箭Neutron目前也在研发中。
ATRC vs RKLB — 直观对比
营收规模更大
RKLB
是对方的1.3倍
$140.5M
营收增速更快
RKLB
高出22.6%
13.1%
自由现金流更多
ATRC
多$132.6M
$-114.2M
两年增速更快
RKLB
近两年复合增速
13.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $140.5M | $179.7M |
| 净利润 | — | $-52.9M |
| 毛利率 | 75.0% | 38.0% |
| 营业利润率 | 1.8% | -28.4% |
| 净利率 | — | -29.5% |
| 营收同比 | 13.1% | 35.7% |
| 净利润同比 | — | -1.1% |
| 每股收益（稀释后） | $0.04 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATRCRKLB
| Q4 25 | $140.5M | $179.7M | ||
| Q3 25 | $134.3M | $155.1M | ||
| Q2 25 | $136.1M | $144.5M | ||
| Q1 25 | $123.6M | $122.6M | ||
| Q4 24 | $124.3M | $132.4M | ||
| Q3 24 | $115.9M | $104.8M | ||
| Q2 24 | $116.3M | $106.3M | ||
| Q1 24 | $108.9M | $92.8M |
净利润ATRCRKLB
| Q4 25 | — | $-52.9M | ||
| Q3 25 | $-267.0K | $-18.3M | ||
| Q2 25 | $-6.2M | $-66.4M | ||
| Q1 25 | $-6.7M | $-60.6M | ||
| Q4 24 | — | $-52.3M | ||
| Q3 24 | $-7.9M | $-51.9M | ||
| Q2 24 | $-8.0M | $-41.6M | ||
| Q1 24 | $-13.3M | $-44.3M |
毛利率ATRCRKLB
| Q4 25 | 75.0% | 38.0% | ||
| Q3 25 | 75.5% | 37.0% | ||
| Q2 25 | 74.5% | 32.1% | ||
| Q1 25 | 74.9% | 28.8% | ||
| Q4 24 | 74.5% | 27.8% | ||
| Q3 24 | 74.9% | 26.7% | ||
| Q2 24 | 74.7% | 25.6% | ||
| Q1 24 | 74.7% | 26.1% |
营业利润率ATRCRKLB
| Q4 25 | 1.8% | -28.4% | ||
| Q3 25 | 0.2% | -38.0% | ||
| Q2 25 | -4.5% | -41.3% | ||
| Q1 25 | -4.8% | -48.3% | ||
| Q4 24 | -11.7% | -38.9% | ||
| Q3 24 | -6.4% | -49.5% | ||
| Q2 24 | -6.2% | -40.7% | ||
| Q1 24 | -10.0% | -46.4% |
净利率ATRCRKLB
| Q4 25 | — | -29.5% | ||
| Q3 25 | -0.2% | -11.8% | ||
| Q2 25 | -4.5% | -46.0% | ||
| Q1 25 | -5.5% | -49.5% | ||
| Q4 24 | — | -39.5% | ||
| Q3 24 | -6.8% | -49.6% | ||
| Q2 24 | -6.9% | -39.2% | ||
| Q1 24 | -12.2% | -47.7% |
每股收益（稀释后）ATRCRKLB
| Q4 25 | $0.04 | $-0.09 | ||
| Q3 25 | $-0.01 | $-0.03 | ||
| Q2 25 | $-0.13 | $-0.13 | ||
| Q1 25 | $-0.14 | $-0.12 | ||
| Q4 24 | $-0.33 | $-0.11 | ||
| Q3 24 | $-0.17 | $-0.10 | ||
| Q2 24 | $-0.17 | $-0.08 | ||
| Q1 24 | $-0.28 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.4M | $1.0B |
| 总债务越低越好 | — | $152.4M |
| 股东权益账面价值 | $491.9M | $1.7B |
| 总资产 | $654.2M | $2.3B |
| 负债/权益比越低杠杆越低 | — | 0.09× |
8季度趋势，按日历期对齐
现金及短期投资ATRCRKLB
| Q4 25 | $167.4M | $1.0B | ||
| Q3 25 | $147.9M | $976.7M | ||
| Q2 25 | $117.8M | $688.1M | ||
| Q1 25 | $99.9M | $428.4M | ||
| Q4 24 | $122.7M | $419.0M | ||
| Q3 24 | $130.3M | $442.4M | ||
| Q2 24 | $114.0M | $496.8M | ||
| Q1 24 | $106.0M | $492.5M |
总债务ATRCRKLB
| Q4 25 | — | $152.4M | ||
| Q3 25 | $61.9M | $347.0M | ||
| Q2 25 | $61.9M | $346.5M | ||
| Q1 25 | $61.9M | $345.9M | ||
| Q4 24 | — | $345.4M | ||
| Q3 24 | $61.9M | $61.2M | ||
| Q2 24 | $61.9M | $64.2M | ||
| Q1 24 | $61.9M | $66.8M |
股东权益ATRCRKLB
| Q4 25 | $491.9M | $1.7B | ||
| Q3 25 | $476.5M | $1.3B | ||
| Q2 25 | $464.5M | $688.5M | ||
| Q1 25 | $454.6M | $431.3M | ||
| Q4 24 | $461.0M | $382.5M | ||
| Q3 24 | $465.0M | $419.8M | ||
| Q2 24 | $462.1M | $455.2M | ||
| Q1 24 | $456.3M | $478.9M |
总资产ATRCRKLB
| Q4 25 | $654.2M | $2.3B | ||
| Q3 25 | $635.4M | $2.2B | ||
| Q2 25 | $608.8M | $1.6B | ||
| Q1 25 | $591.6M | $1.3B | ||
| Q4 24 | $609.3M | $1.2B | ||
| Q3 24 | $615.1M | $1.2B | ||
| Q2 24 | $597.3M | $1.2B | ||
| Q1 24 | $591.6M | $1.2B |
负债/权益比ATRCRKLB
| Q4 25 | — | 0.09× | ||
| Q3 25 | 0.13× | 0.27× | ||
| Q2 25 | 0.13× | 0.50× | ||
| Q1 25 | 0.14× | 0.80× | ||
| Q4 24 | — | 0.90× | ||
| Q3 24 | 0.13× | 0.15× | ||
| Q2 24 | 0.13× | 0.14× | ||
| Q1 24 | 0.14× | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $20.0M | $-64.5M |
| 自由现金流经营现金流 - 资本支出 | $18.4M | $-114.2M |
| 自由现金流率自由现金流/营收 | 13.1% | -63.6% |
| 资本支出强度资本支出/营收 | 1.1% | 27.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $48.3M | $-321.8M |
8季度趋势，按日历期对齐
经营现金流ATRCRKLB
| Q4 25 | $20.0M | $-64.5M | ||
| Q3 25 | $26.7M | $-23.5M | ||
| Q2 25 | $21.6M | $-23.2M | ||
| Q1 25 | $-11.0M | $-54.2M | ||
| Q4 24 | $5.8M | $-2.4M | ||
| Q3 24 | $20.0M | $-30.9M | ||
| Q2 24 | $7.4M | $-13.0M | ||
| Q1 24 | $-21.0M | $-2.6M |
自由现金流ATRCRKLB
| Q4 25 | $18.4M | $-114.2M | ||
| Q3 25 | $24.1M | $-69.4M | ||
| Q2 25 | $19.0M | $-55.3M | ||
| Q1 25 | $-13.2M | $-82.9M | ||
| Q4 24 | $3.1M | $-23.9M | ||
| Q3 24 | $16.4M | $-41.9M | ||
| Q2 24 | $5.0M | $-28.3M | ||
| Q1 24 | $-23.8M | $-21.8M |
自由现金流率ATRCRKLB
| Q4 25 | 13.1% | -63.6% | ||
| Q3 25 | 18.0% | -44.8% | ||
| Q2 25 | 13.9% | -38.3% | ||
| Q1 25 | -10.7% | -67.6% | ||
| Q4 24 | 2.5% | -18.1% | ||
| Q3 24 | 14.1% | -40.0% | ||
| Q2 24 | 4.3% | -26.7% | ||
| Q1 24 | -21.9% | -23.5% |
资本支出强度ATRCRKLB
| Q4 25 | 1.1% | 27.6% | ||
| Q3 25 | 1.9% | 29.6% | ||
| Q2 25 | 2.0% | 22.2% | ||
| Q1 25 | 1.8% | 23.4% | ||
| Q4 24 | 2.2% | 16.3% | ||
| Q3 24 | 3.1% | 10.5% | ||
| Q2 24 | 2.1% | 14.4% | ||
| Q1 24 | 2.5% | 20.7% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATRC
| Appendage Management | $45.5M | 32% |
| Openheart | $38.5M | 27% |
| Other | $26.2M | 19% |
| Pain Management | $22.6M | 16% |
| Minimally Invasive | $7.7M | 6% |
RKLB
| Products | $94.0M | 52% |
| Transferred Over Time | $87.3M | 49% |
